TY - JOUR
T1 - Evaluation of the Diagnostic Performance of a Semiquantitative Cryptococcal Antigen Point-of-Care Assay among HIV-Infected Persons with Cryptococcal Meningitis
AU - Tadeo, Kiiza Kandole
AU - Nimwesiga, Audrey
AU - Kwizera, Richard
AU - Apeduno, Lucy
AU - Martyn, Emily
AU - Okirwoth, Michael
AU - Nalintya, Elizabeth
AU - Rajasingham, Radha
AU - Williams, Darlisha A.
AU - Rhein, Joshua
AU - Meya, David B.
AU - Kafufu, Bosco
AU - Boulware, David R.
AU - Skipper, Caleb P.
N1 - Publisher Copyright:
© 2021 American Society for Microbiology.
PY - 2021/7
Y1 - 2021/7
N2 - A newly developed cryptococcal antigen (CrAg) semiquantitative (SQ) lateral flow assay (LFA) provides a semiquantitative result in a rapid one-step test instead of performing serial dilutions to determine CrAg titer. We prospectively compared the diagnostic performance of the CrAgSQ assay (IMMY) with the CrAg LFA (IMMY) on cerebrospinal fluid (CSF) samples collected from persons with HIV-associated meningitis. The CrAgSQ grades (11 to 51) were compared with CrAg LFA titers and quantitative CSF fungal cultures. Among 87 participants screened for HIV-associated meningitis, 60 had cryptococcal meningitis (59 CrAg positive [CrAg1] by LFA and 1 false negative due to prozone with CrAg LFA titer of 1:1,310,000 and culture positivity), and 27 had no cryptococcal meningitis by CrAg LFA or culture. The CrAgSQ on CSF had 100% (60/60) sensitivity and 100% specificity (27/27). CSF CrAg titers ranged from 1:5 to 1:42 million. CrAgSQ grades of 11, 21, 31, 41, and 51 corresponded to median CrAg LFA titers of 1:,10, 1:60, 1:7,680, 1:81,920, and 1:1,474,000, respectively. CSF CrAgSQ grades 31 or higher were always CSF culture positive. Mortality at 14 days for those with low CrAgSQ grade (11 to 31) was 5% (1/22) versus 21% (8/38) with high CrAgSQ grades (41 to 51) (P = 0.084). The CrAgSQ demonstrates excellent diagnostic performance, maintaining both the sensitivity and specificity of the CrAg LFA, and counters false-negative prozone effects. The CrAgSQ assay reading is more complex but does provide useful clinical information about disease burden and probability of culture positivity in a single rapid diagnostic test.
AB - A newly developed cryptococcal antigen (CrAg) semiquantitative (SQ) lateral flow assay (LFA) provides a semiquantitative result in a rapid one-step test instead of performing serial dilutions to determine CrAg titer. We prospectively compared the diagnostic performance of the CrAgSQ assay (IMMY) with the CrAg LFA (IMMY) on cerebrospinal fluid (CSF) samples collected from persons with HIV-associated meningitis. The CrAgSQ grades (11 to 51) were compared with CrAg LFA titers and quantitative CSF fungal cultures. Among 87 participants screened for HIV-associated meningitis, 60 had cryptococcal meningitis (59 CrAg positive [CrAg1] by LFA and 1 false negative due to prozone with CrAg LFA titer of 1:1,310,000 and culture positivity), and 27 had no cryptococcal meningitis by CrAg LFA or culture. The CrAgSQ on CSF had 100% (60/60) sensitivity and 100% specificity (27/27). CSF CrAg titers ranged from 1:5 to 1:42 million. CrAgSQ grades of 11, 21, 31, 41, and 51 corresponded to median CrAg LFA titers of 1:,10, 1:60, 1:7,680, 1:81,920, and 1:1,474,000, respectively. CSF CrAgSQ grades 31 or higher were always CSF culture positive. Mortality at 14 days for those with low CrAgSQ grade (11 to 31) was 5% (1/22) versus 21% (8/38) with high CrAgSQ grades (41 to 51) (P = 0.084). The CrAgSQ demonstrates excellent diagnostic performance, maintaining both the sensitivity and specificity of the CrAg LFA, and counters false-negative prozone effects. The CrAgSQ assay reading is more complex but does provide useful clinical information about disease burden and probability of culture positivity in a single rapid diagnostic test.
KW - Cryptococcus
KW - HIV
KW - cryptococcal antigen
KW - cryptococcal meningitis
KW - semiquantitative assay
KW - semiquantitative lateral flow assay
UR - http://www.scopus.com/inward/record.url?scp=85112127072&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112127072&partnerID=8YFLogxK
U2 - 10.1128/jcm.00860-21
DO - 10.1128/jcm.00860-21
M3 - Article
C2 - 34076472
AN - SCOPUS:85112127072
SN - 0095-1137
VL - 59
JO - Journal of clinical microbiology
JF - Journal of clinical microbiology
IS - 8
M1 - e00860-21
ER -